DR. RONALD FAIRBAIRN PARSONS, MD

Plain English
This paper examines kidney transplant patients who have a very high level of sensitization, meaning their bodies are highly likely to reject a donor kidney. It found that new strategies, like better matching systems and innovative treatments such as desensitization therapies, have improved transplant chances for many of these patients. Despite these advancements, those with a sensitization level of 99.9% or higher still struggle to find a match, so ongoing developments in personalized treatment methods are essential for them. Who this helps: This helps highly sensitized kidney transplant patients and their doctors.

Plain English
This study looked at different methods for assessing frailty in patients who are being evaluated for kidney transplants. Researchers examined 430 patients and found that over half (52.2%) were considered frail by at least one method. The study revealed that two of the methods (PMA and FRS) identified more frail patients compared to the Fried frailty phenotype, but overall, the different methods didn't agree well with each other. Who this helps: This helps doctors and healthcare providers determine how to better evaluate and list patients for kidney transplants.

Plain English
This study looked at how kidney transplant patients transition from specialized transplant centers to their regular kidney doctors, or nephrologists. Researchers found that as more patients are living longer after their transplants, it's essential for nephrologists to work closely with transplant centers for better ongoing care. The conference proposed new strategies to improve communication and collaboration, which will help ensure that these patients get the comprehensive support they need. Who this helps: This benefits kidney transplant patients and their healthcare providers.

Plain English
This research focused on a problem called delayed graft function (DGF), which happens when a transplanted kidney doesn’t work immediately. Experts from the National Kidney Foundation gathered to review what is known about DGF and found that the current definitions and approaches aren’t helping advance understanding or treatment. They proposed a new way to define DGF and discussed better management practices and future research priorities to improve outcomes for kidney transplant patients. Who this helps: Patients receiving kidney transplants.

Plain English
This study looked at improving guidelines for detecting different types of organ rejection in pancreas transplant patients, focusing on both T cell-mediated and antibody-mediated rejections. Key updates include new ways to describe these rejections, the introduction of non-invasive methods like analyzing donor-derived DNA, and the use of biopsies from a specific part of the intestine as alternatives to traditional pancreas biopsies. These enhancements can help doctors make better decisions about patient care after a pancreas transplant. Who this helps: This benefits patients undergoing pancreas transplants and the doctors who care for them.

Plain English
This study looked at what happens when a pancreas transplant doesn't work anymore, known as a failed pancreas allograft, and how to manage it. Researchers found that patients with a failed transplant can face serious health issues and a high risk of death, but those who are carefully chosen for a second transplant can still have good outcomes. The study emphasizes the importance of considering other health factors in patients to improve their chances for a successful retransplant. Who this helps: This helps patients who have experienced pancreas transplant failure and may be considering retransplantation.

Plain English
This study looked at how pancreas transplant biopsies are performed across the United States, including the challenges doctors face. Researchers surveyed 76 out of 117 active transplant centers, finding that 34% of programs rarely or never use biopsies, often opting to treat rejection based on assumptions instead. The main issues include doctors' lack of confidence in performing biopsies and interpreting the results accurately, which can lead to inconsistent care for transplant patients. Who this helps: Patients receiving pancreas transplants benefit from improved biopsy practices and more accurate diagnosis of rejection.

Plain English
This research paper examines the barriers that prevent people from receiving kidney transplants and proposes ways to improve access to this life-saving treatment. It highlights that while kidney transplants lead to better health outcomes and reduced costs, many patients still face challenges in getting one. To address these issues, the authors recommend better education for patients, improved communication among healthcare providers, and increased use of telemedicine and living donations. Who this helps: This helps patients in need of a kidney transplant and their families.

Plain English
This research looked at a special kind of structure called phylloclades, which some plants use instead of traditional leaves for photosynthesis. The study found that different plants have phylloclades that adapt to their environments, like the broad phylloclades of Phyllocladus in wet, low-light areas and the more drought-resistant features of Ruscus found in dry habitats. Understanding these unique structures helps scientists learn how plants evolve and adapt, which is important for conservation and agriculture. Who this helps: This helps botanists and ecologists studying plant adaptation and resilience.

Plain English
This study looked at how U.S. kidney transplant programs manage the transition of stable patients back to their regular kidney doctors. It found that 39% of programs fully transfer care, while 48% keep working together with the patient's referring doctor. Key reasons for transitioning include how far patients live (64% of the time) and the need to maintain a good relationship with local doctors (58% each for continuity of care and reducing the workload on transplant centers). Who this helps: This helps kidney transplant patients and their nephrologists.

Plain English
This study focused on improving pancreas transplantation in the U.S. for patients with insulin-dependent diabetes, as the number of these transplants has significantly declined over the past 20 years. Experts identified 16 challenges that are stopping patients from getting transplants and proposed 44 strategies to tackle these issues, including better selection processes for candidates and increased education and collaboration among healthcare providers. These changes are crucial because they aim to make pancreas transplants more accessible and successful, ultimately helping improve patients' lives. Who this helps: This helps patients with diabetes who are considering pancreas transplantation.

Plain English
This study looked at the issue of frailty in patients who are candidates for or recipients of pancreas transplants, especially those with kidney disease and diabetes. Researchers found that older patients and those with long-term diabetes are more likely to be frail, which can affect their transplant outcomes. Understanding and measuring frailty is crucial for improving patient selection and management after transplantation. Who this helps: Patients undergoing pancreas transplantation and their healthcare providers.

Plain English
This study looked at how COVID-19 infection and vaccination affect HLA antibodies in patients waiting for kidney transplants. Out of 409 patients, only 6.4% showed any change in their HLA antibody levels after infection or vaccination, with the majority remaining stable. This is important because it means that COVID-19 and vaccination have little effect on the compatibility of organ transplants, and hospitals can continue their vaccination programs without concern about impacting transplant eligibility. Who this helps: This helps kidney transplant candidates and healthcare providers.

Plain English
This study explored how general kidney doctors (nephrologists) manage patients with failing kidney transplants and found that over 60% think getting patients listed for a new kidney is the biggest priority, followed by managing medications and noting the risk of death. The research showed that practices vary widely; for example, 60% of nephrologists would stop certain medications first when managing a failing transplant, while others wait for guidance from transplant specialists. Improving communication and creating clearer guidelines for these transitions could lead to better care for these patients. Who this helps: This helps patients with kidney transplants and their doctors.

Plain English
This study looked at whether kidney transplant patients who receive belatacept every two months, instead of every month, can have similar kidney function over a year. They found that the every two-month dosing was just as effective, with no significant differences in kidney function measurements, and it was safe, showing no patient deaths or organ losses. This research is important because it makes belatacept easier to use, which could help more patients maintain their kidney transplants without frequent visits to the hospital. Who this helps: This helps kidney transplant patients by offering a more convenient treatment option.

Plain English
This study looked at how hospitals and organizations manage and report COVID-19 test results for organs donated after death. The researchers found that while there was a need for quick and accurate reporting of these results, the way this information was collected and shared varied widely across the country. Having consistent and clear reporting processes is crucial for making sure organs are used effectively, especially during health crises like the pandemic. Who this helps: This benefits transplant centers and organ procurement organizations, as well as patients waiting for organ transplants.

Plain English
This study looked at the roles and backgrounds of medical directors running kidney and pancreas transplant programs across the U.S. Out of 183 surveyed directors, 123 responded, revealing that many are over 50 years old (61%); most are male (80%); and only half had formal training in transplant leadership. Many spend a lot of their time (50-75%) on clinical duties rather than administrative tasks, highlighting a need for better training in management and leadership. Who this helps: This benefits patients by ensuring transplant programs are led by well-trained directors who can effectively manage their care.

Plain English
This study looked at how to care for kidney transplant patients whose grafts are failing. Researchers found that patients who go back to dialysis after their transplant face higher health risks, but there is not enough agreement among doctors on how to adjust their medications during this time. By suggesting better coordination between specialists and general doctors, the study aims to improve health outcomes for these patients as they prepare for more treatment options. Who this helps: This helps kidney transplant patients and their doctors.

Plain English
This paper looks at the current state of cellular transplantation, which includes using cells from donors or animals to treat diseases, compared to traditional organ transplants. It highlights that while cellular transplantation is less common now, there is great potential for growth, especially with advancements like 3D bioprinting and better regulatory support. The authors call for more funding and a reevaluation of how these cellular therapies are regulated, to make them safer and more effective alternatives to organ transplants. Who this helps: This benefits patients needing transplants, doctors involved in transplantation, and researchers in regenerative medicine.

Plain English
This study looked at why the number of pancreas transplants in the U.S. has dropped over the past 15 years, gathering insights from 123 programs. Researchers found that 82% of programs think the number of transplants is not meeting patient needs and noted that high-volume centers are more likely to expand the types of patients eligible for transplants and use more aggressive donor practices. This matters because it highlights a gap between the demand for pancreas transplants and the number being performed, potentially leaving many diabetics without needed treatment options. Who this helps: Patients with diabetes who may benefit from pancreas transplants.

Plain English
This study looked at how kidney transplant programs in the U.S. view and assess frailty, which refers to a person's overall health and ability to handle stress. Out of 202 transplant programs surveyed, 99% believe frailty is important in deciding who should get a transplant, with 38% assessing frailty in all candidates. However, there are many different methods used to measure frailty, leading to inconsistencies in who gets evaluated and how. Who this helps: This benefits patients and doctors by improving the process of evaluating kidney transplant candidates.

Plain English
This study focused on how a medication called belatacept affects certain antibodies in kidney transplant patients who have a high level of immune sensitivity. In a group of 163 patients with very high antibody levels, those who received belatacept saw a significant decrease in harmful antibodies—specifically, there was a 99% reduction for class I antibodies and lower overall sensitivity (P<.01). This is important because it could help more patients become eligible for kidney transplants by improving compatibility with donor organs. Who this helps: This benefits kidney transplant patients who are highly sensitized and struggling to find suitable donor matches.

Plain English
This paper reviews studies on frailty in people undergoing kidney transplants, focusing on how frailty affects their health before and after surgery. It found that about 20% of kidney transplant recipients are frail, and these patients are twice as likely to die compared to those who are not frail. Understanding and measuring frailty can help identify who needs additional support during their treatment and potentially improve their outcomes. Who this helps: This research benefits kidney transplant patients and doctors by highlighting the importance of addressing frailty in treatment plans.

Plain English
This study looked at how a patient's functional status, or ability to perform daily activities, affects survival rates after they receive a simultaneous pancreas-kidney transplant (SPKT). The researchers analyzed data from nearly 17,000 patients and found that those with lower functional scores had a higher mortality rate after the transplant; for example, the risk of death was 55% higher for disabled patients compared to those with normal functioning. However, SPKT significantly improves long-term survival for all patients, especially after the first 30 days post-transplant. Who this helps: This helps patients needing simultaneous pancreas-kidney transplants, as well as doctors evaluating transplant options.

Plain English
This research looked at a medication called belatacept, which helps prevent the immune system from creating harmful antibodies after organ transplants. The findings showed that belatacept effectively stops new antibody responses and can manage existing antibodies, which is important for the long-term success of transplants. Understanding how belatacept works will help improve future treatments to ensure better transplant outcomes. Who this helps: This benefits transplant patients and their doctors.

Plain English
This study looked at how a new kidney allocation system in the U.S. is helping patients with higher levels of antibodies, known as highly sensitized recipients, get kidney transplants. The review from five transplant centers showed that these patients, who make up about 5.5% to 9.2% of all candidates, experienced increased transplant rates ranging from 12.4% to 27%. This is important because it means more of these disadvantaged patients are getting the organs they need, but there are concerns about costs and resources used in the process that need further evaluation. Who this helps: This benefits highly sensitized kidney patients who struggle to find suitable donors.

Plain English
This study looked at how a treatment called anti-IL-5 immunotherapy affects long-lasting immune cells known as plasma cells, which produce antibodies that interfere with organ transplantation. Researchers found that this treatment reduced the number of these problematic plasma cells but did not completely eliminate them; however, unlike other methods, it did not cause harsh side effects, like significant weight loss. This matters because it presents a potentially safer alternative for patients awaiting transplants who need to reduce harmful antibodies from their bodies. Who this helps: This benefits patients who require organ transplants.

Plain English
This study looked at different preservation solutions used to store organs (like kidneys, livers, and pancreases) before transplantation to find out which works best. It found that while popular solutions like University of Wisconsin, HTK, and Celsior often show similar outcomes, newer data suggests that University of Wisconsin is still the most reliable choice, especially for long-term success after kidney and liver transplants. This matters because selecting the right preservation solution can significantly impact how well transplanted organs function in patients. Who this helps: Patients receiving organ transplants.

Plain English
Patients with liver cancer receive transplant priority points under MELD exception rules, but the benefit varies by geographic region depending on organ availability. Comparing regions with long versus short wait times, this study found that priority allocation for hepatocellular carcinoma led to similar survival outcomes regardless of waiting time, with some regional disparities. The findings informed ongoing debates about how to fairly prioritize cancer patients for transplant.

Plain English
After a living donor gives part of their liver, delayed stomach emptying is a recognized but poorly understood complication. This study characterized the incidence, risk factors, and management—including the need for endoscopy or reoperation—after living donor hepatectomy. Awareness of this complication can guide post-operative monitoring and earlier intervention.

Plain English
This study investigated whether a drug called bortezomib could help eliminate harmful antibodies that prevent successful organ transplants in mice. The researchers found that mice treated with bortezomib had a significant drop in these antibodies, with a complete elimination of donor-specific antibodies after treatment, while control mice maintained high levels of these antibodies. This is important because it suggests a new method for preventing organ rejection in transplants, potentially leading to better outcomes for patients. Who this helps: This helps patients needing organ transplants and doctors working in transplant medicine.

Plain English
This study looked at how the B cells in the immune system can be trained to stop attacking transplanted organs. Researchers believe that by focusing on B cells, in addition to T cells, we can improve the chances of transplant success. They propose that using targeted treatments for B cells could help reduce the production of harmful antibodies against transplanted organs, which is crucial for long-term transplant survival. Who this helps: This helps transplant patients.

Plain English
This study looked at the use of A2 ABO incompatible kidneys for transplant and how it affects waiting times and kidney survival rates. Researchers found that only 15% of available A2 kidneys were used for incompatible recipients, even though patients with A2 kidneys had shorter waiting times—337 days for O recipients versus 684 days for O-to-O transplants. Importantly, the five-year survival rates for the transplants were similar across blood types, with rates around 84% to 86%. Who this helps: This benefits kidney transplant candidates and improves access to life-saving organs.

Plain English
This study looked at a treatment that blocks a protein called BLyS to help prevent rejection of transplanted islets (clusters of insulin-producing cells) in mice. The researchers found that when they used this treatment, the transplanted islets survived for a long time without being rejected, showing successful long-term acceptance. Specifically, they noticed that B cells that usually produce antibodies to attack the graft were significantly reduced, leading to better outcomes in the transplanted animals. Who this helps: This research can benefit patients receiving organ transplants by improving graft survival and reducing rejection rates.

Plain English
This study looked at how the immune system, specifically B lymphocytes (a type of white blood cell), can be trained to not react against transplanted organs. The researchers found that when certain B cells developed in the presence of cells from the donor, they did not produce antibodies that would attack the donated organ, even though other immune responses were still active. This is important because it shows a way to promote tolerance to transplanted organs and potentially improve transplant success rates. Who this helps: This helps transplant patients by reducing the risk of organ rejection.

Plain English
This study looked at how to make the immune system accept transplanted organs better by targeting B-cells, which are a type of immune cell that can cause rejection. The researchers found that by using new therapies aimed at changing how B-cells respond to the donor's tissue, they could help the body tolerate the transplant without the need for strong immunosuppressive drugs. This is important because it could lead to better long-term survival of transplanted organs. Who this helps: Patients receiving organ transplants.

Plain English
The study focused on how B-lymphocytes (a type of white blood cell) behave and can be treated in organ transplant patients to prevent rejection. Researchers found that eliminating these B-cells immediately after transplant could help avoid sensitization, which leads to chronic rejection; they highlighted a key survival factor called BLyS that influences B-cell development and tolerance. Targeting BLyS could be a new strategy to enhance long-term success in transplants by reshaping the B-cell population to avoid harmful responses against the transplanted organ. Who this helps: This helps transplant patients by reducing the risk of chronic rejection and improving transplant outcomes.

Plain English
This study explored how to prevent harmful immune responses from B cells in organ transplant patients. The researchers found that teaching B cells to tolerate transplanted organs could help improve transplant survival. They suggest focusing on specific targets in B cells, which could lead to new treatments in future clinical trials. Who this helps: This benefits transplant patients by increasing the chances of their new organs being accepted.

Plain English
This study looked at how different groups of B lymphocytes (a type of immune cell) stay balanced in the body and how these processes change with age. Researchers found that specific proteins called BLyS ligands and receptors play a key role in keeping these immune cells alive and functioning. Understanding these mechanisms is important because it can help us figure out how to better support immune health as people get older. Who this helps: This research benefits patients, especially older adults, by improving our understanding of immune system changes with age.

Plain English
This study looked at a treatment that targets a protein called BLyS/BAFF to help stop autoimmune diabetes in mice. The researchers found that using this treatment led to a lower number of harmful B cells and a significant reduction in diabetes cases, with 70% of the mice remaining diabetes-free compared to untreated mice. This matters because it shows a potential way to prevent autoimmune diabetes before it starts, which could lead to better outcomes for patients at risk. Who this helps: Patients at risk of developing autoimmune diabetes.